Datasheet for ABIN966218

anti-GPC1 antibody (C-Term)

1 Publication

Go to Product page

Overview

Quantity:	0.1 mg
Target:	GPC1
Binding Specificity:	C-Term
Reactivity:	Human, Mouse
Host:	Rabbit
Clonality:	Polyclonal
Application:	Immunohistochemistry (IHC)

Product Details

Immunogen:	Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to C-terminal residues of human GPC1(Glypican-1 precursor)
Purification:	Purified by antigen-specific affinity chromatography.

Target Details

Target:	GPC1
Alternative Name:	GPC1 (GPC1 Products)
Background:	GPC1(Glypican-1) is a cell surface proteoglycan that bears heparan sulfate. The protein is attached to the membrane by a GPI-anchor. This cell-associated glypican is further processed to give rise to a medium-released species. The glypican-1 is required for efficient TGF-beta1 signaling in pancreatic cancer cells. The syndecan-1 and glypican-1 have roles in progression of ovarian cancer. Cell surface heparan sulfate proteoglycans are composed of a membrane-

Target Details

	associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation.
Pathways:	Glycosaminoglycan Metabolic Process, Regulation of Muscle Cell Differentiation

Application Details

Application Notes:	ELISA, Western blotting: 1µg/ml for 2hrs.
Restrictions:	For Research Use only

Handling

Format:	Liquid
Buffer:	This antibody is stored in PBS, 50% glycerol
Preservative:	Sodium azide
Precaution of Use:	This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	-20 °C

Publications

Product cited in:	Van Meir, Roemer, Diserens, Kikuchi, Rempel, Haas, Huang, Friedmann, de Tribolet, Cavenee: " Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells." in: **Proceedings of the National Academy of Sciences of the United States of America**, Vol. 92, Issue 4, pp. 1008-12, (1995) (PubMed). Jacquemier, Molès, Penault-Llorca, Adélaide, Torrente, Viens, Birnbaum, Theillet: "p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results." in: **British journal of cancer**, Vol. 69, Issue 5, pp. 846-52, (1994) (PubMed). Mørkve, Halvorsen, Stangeland, Gulsvik, Laerum: "Quantitation of biological tumor markers (p53, c-myc, Ki-67 and DNA ploidy) by multiparameter flow cytometry in non-small-cell lung cancer." in: **International journal of cancer. Journal international du cancer**, Vol. 52, Issue 6,

pp. 851-5, (1993) (PubMed).

van den Berg, Baas, Polak, Offerhaus: "Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid." in: **The American journal of pathology**, Vol. 142, Issue 2, pp. 381-5, (1993) (PubMed).

Yeargin, Cheng, Yu, Gjerset, Bogart, Haas: "P53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines." in: **The Journal of clinical investigation**, Vol. 91, Issue 5, pp. 2111-7, (1993) (PubMed).